merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Safety and FDA approval - Eli Lilly's offering is positioning its vials as a safer, FDA-approved alternative to compounded drugs that lack the same level of oversight</answer>

<question_number>2</question_number>
<answer>By creating its own telehealth platform that connects patients with providers and offering direct-to-door delivery of vials at competitive prices, mimicking the same business model but with FDA-approved products</answer>

<question_number>3</question_number>
<answer>Lack of safety, quality, and effectiveness standards due to less regulatory oversight of compounded medications</answer>

<question_number>4</question_number>
<answer>To regain customers who are currently getting compounded tirzepatide, prioritizing market share recovery over maximizing profit per customer</answer>

<question_number>5</question_number>
<answer>Compounding pharmacies can only legally produce alternatives to medications on the FDA's shortage list; if tirzepatide is removed, compounded versions would become illegal</answer>

<question_number>6</question_number>
<answer>By "removing third-party supply chain entities" to offer "transparent pricing" through direct sales</answer>

<question_number>7</question_number>
<answer>Older Medicare patients might access these drugs at lower prices but face increased risks of fractures or frailty due to muscle loss without proper insurance coverage and medical supervision</answer>

<question_number>8</question_number>
<answer>It could make patients more aware of potential safety concerns with compounded versions by highlighting that Eli Lilly's vials are FDA-approved while compounded alternatives have less oversight</answer>

<question_number>9</question_number>
<answer>Being listed on the FDA's "shortage" list</answer>

<question_number>10</question_number>
<answer>Lower pricing</answer>